Altman Health Investments

Jason Altman serves as Managing Partner and is the primary decision-maker for all capital deployment. He operates a concentrated seed-stage portfolio, sourcing and leading rounds with direct founder engagement. The firm does not have a multi-tier investment committee structure, aligning with a solo-GP venture model common among specialized health-tech seed funds.

Deal flow originates primarily through Altman's network within the Boston and broader Northeast academic medical center ecosystem, health-tech angel syndicates, and relationships with incubators tied to institutions like Harvard and MIT. His focus on companies navigating regulatory and reimbursement complexity gives him early visibility into ventures that require specialist capital rather than generalist tech dollars.

The firm's historical posture centers on direct equity and co-investment at the seed and early-growth stages. Evidence of parallel fund-of-funds or LP commitments into external health-tech vehicles is minimal. Altman's model favors direct founder exposure and board-level engagement over intermediary fund structures.

The firm targets digital health, healthcare IT, and enterprise software for providers, payers, and life sciences companies. Sub-sectors of interest include clinical workflow automation, patient engagement platforms, revenue cycle management, and data interoperability tools. Altman does not invest in therapeutics, medical devices requiring extensive FDA PMA approval, or consumer wellness apps decoupled from clinical reimbursement pathways.

There is no public structural relationship between Altman Health Investments and Altman Capital (the family office of Sam Altman) or any other Altman-branded financial entity. Jason Altman's firm is independently operated out of Medford, MA, and focused exclusively on seed-stage health-tech. Any similarity in name is coincidental, and the firms have no known shared principals, capital, or portfolio overlap.